Entera Bio (NASDAQ:ENTX) Stock Price Up 6.9% – What’s Next?

Entera Bio Ltd. (NASDAQ:ENTX) shares were up 6.9% on Wednesday. The stock traded as high as $2.86 and last traded at $2.8750. 397,909 shares traded hands during mid-day trading, a decline of 61% from the average daily volume of 1,022,903 shares. The stock had previously closed at $2.69.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Leerink Partners initiated coverage on shares of Entera Bio in a research note on Friday, September 18th. They set an “outperform” rating and a $9.00 price objective for the company. Lifesci Capital began coverage on Entera Bio in a report on Wednesday, September 23rd. They issued an “outperform” rating and a $10.00 price objective on the stock. Cantor Fitzgerald began coverage on shares of Entera Bio in a research report on Tuesday, September 22nd. They set an “overweight” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a research note on Friday, July 17th. Finally, Wall Street Zen upgraded shares of Entera Bio to a “sell” rating in a report on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $9.60.

Entera Bio Trading Down 0.7%

The firm has a 50 day moving average of $2.96 and a 200-day moving average of $1.91. The company has a market cap of $502.63 million, a P/E ratio of -8.26 and a beta of 1.40.

Entera Bio (NASDAQ:ENTX) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.06). Equities analysts predict that Entera Bio Ltd. will post -0.4 EPS for the current fiscal year.

Institutional Trading of Entera Bio

An institutional investor recently raised its position in Entera Bio stock. Seven Fleet Capital Management LP raised its holdings in Entera Bio Ltd. (NASDAQ:ENTX) by 51.9% in the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 205,542 shares of the company’s stock after buying an additional 70,224 shares during the quarter. Seven Fleet Capital Management LP owned about 0.42% of Entera Bio worth $228,000 at the end of the most recent reporting period. 14.11% of the stock is owned by institutional investors and hedge funds.

Entera Bio Company Profile

Entera Bio Ltd. is a biotechnology company developing orally administered therapies based on large-molecule drugs, including proteins and peptides that are traditionally delivered by injection. The company’s proprietary delivery technology is designed to help these molecules pass through the gastrointestinal tract and reach the bloodstream, with the goal of improving convenience and patient adherence.

Entera Bio’s lead programs have focused on bone and mineral disorders. Its pipeline has included EB613, an oral formulation of parathyroid hormone (PTH 1-34, or teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral PTH product candidate intended for hypoparathyroidism.